Clinical research of “Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites

ZHU Jun-feng; WANG Ling-tai

您当前的位置：

首页 >

文章列表页 >

Clinical research of “Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites

更新时间：2022-08-31

- Clinical research of “Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites
- Shanghai Journal of Traditional Chinese Medicine Vol. 50, Issue 4, Pages: 37-40(2016)
- 作者机构：
  
  1. 上海中医药大学附属市中医医院肝病科,上海,200071
  2. 上海中医药大学附属曙光医院肝病科,上海,201203
- 作者简介：
- 基金信息：
- DOI：
  CLC：
扫描看全文
ZHU Jun-feng, WANG Ling-tai. Clinical research of “Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites. [J]. Shanghai Journal of Traditional Chinese Medicine 50(4):37-40(2016)
DOI：

ZHU Jun-feng, WANG Ling-tai. Clinical research of “Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites. [J]. Shanghai Journal of Traditional Chinese Medicine 50(4):37-40(2016) DOI：

摘要

目的：观察“水臌贴”敷脐联合托伐普坦等治疗慢性乙型肝炎肝硬化顽固性腹水的临床疗效。方法：将65例慢性乙型肝炎肝硬化顽固性腹水患者随机分为治疗组(33例)和对照组(32例)。对照组予托伐普坦等常规西药,治疗组在对照组治疗方案基础上加用“水臌贴”敷脐。两组疗程均为14天,观察临床疗效,比较临床体征(24 h尿量、腹围、体质量)、彩超下相关指标(门静脉血流量、脾静脉血流量及腹水暗区深度等)、肝功能及钠水平(血钠、尿钠)的变化情况。结果：①治疗组、对照组临床总有效率分别为81.82%和62.50%；组间临床疗效比较,治疗组显著优于对照组(P<0.05)。②治疗前与随访后组内比较,两组24 h尿量均明显增多(P<0.05),腹围均明显缩小(P<0.05)；组间随访后比较,24 h尿量、腹围水平差异有统计学意义,治疗组改善程度优于对照组(P<0.05)。③治疗前后组内比较,治疗组门静脉血流量、脾静脉血流量及腹水暗区深度差异均有统计学意义(P<0.05)；组间治疗后比较,门静脉血流量、脾静脉血流量及腹水暗区深度差异有统计学意义,治疗组改善程度优于对照组(P<0.05)。④治疗前后组内比较,治疗组肝功能指标差异均有统计学意义(P<0.05),对照组除GGT、A/G以外,其余指标差异均有统计学意义(P<0.05)；组间治疗后比较,GGT、TBIL、ALB、A/G水平差异有统计学意义(P<0.05)。⑤治疗前后组内比较,两组血钠和尿钠水平均差异有统计学意义(P<0.05)；组间治疗后比较,血钠和尿钠水平差异无统计学意义(P>0.05)。结论：“水臌贴”敷脐联合托伐普坦等治疗慢性乙型肝炎肝硬化顽固性腹水的疗效较佳,可显著缓解临床体征,减少腹水量。

Abstract

Objective:To observe the clinical efficacy of “Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites. Methods 65 cases of patients with refractory cirrhosis ascites were randomized into treatment group (33 cases) and control group (32 cases). The control group was treated with Tolvaptan orally；the treatment group was treated with “Shuigu Cataplasm” umbilical compressing based on the treatment of control group. Two groups were treated for 14 days. The clinical efficacy was observed. The changes of clinical sign (24h urine volume,abdominal girth,body mass),index of correlation tested with color Doppler ultrasound(blood flow volume of portal vein,blood flow volume of splenic vein,depth of ascites dark space),liver function,levels of sodium in blood and urine. Results: ①The total effective rate of the treatment group and control group were 81.82%和62.50% respectively; the difference of clinical efficacy between the two groups was statistically significant(P<0.05). ②Compared before treatment and after follow-up,the difference of 24h urine volume,abdominal girth of the two groups were significant(P<0.05)；after the follow-up,the difference of 24h urine volume,abdominal girth between the two groups were significant(P<0.05). ③Compared before and after the treatment,the difference of blood flow volume of portal vein,blood flow volume of splenic vein and depth of ascites dark space of the two groups were significant(P<0.05)；after the treatment,the difference of blood flow volume of portal vein,blood flow volume of splenic vein and depth of ascites dark space between the two groups were significant(P<0.05). ④Compared before and after the treatment,the difference of liver function index of the treatment group were all significant(P<0.05),while only the difference of GGT, TBIL, ALB, A/G levels of control group were significant(P<0.05). After the treatment,the difference of GGT, TBIL, ALB, A/G levels between the two groups were significant(P<0.05).⑤Compared before and after the treatment,the difference of sodium levels in blood and urine of the two groups were significant(P<0.05)；after the treatment,there was no significant difference in sodium levels of blood and urine between the two groups(P>0.05). Conclusion: “Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites,can improve the clinical sign,relieve the abdominal water volume of the patients.

关键词

肝硬化顽固性腹水慢性乙型肝炎水臌贴托伐普坦敷脐疗法门/脾静脉血流量腹水暗区深度

Keywords

liver cirrhosisrefractory asciteschronic hepatitis B“Shuigu Cataplasm”Tolvaptanumbilical compressing theropyblood flow volume of portal / splenic veindepth of ascites dark space

references

Views

285

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Review and commentary of refractory cirrhotic ascites with diagnosis and treatment of integrative medicine

Clinical observation on treatment of refractory ascites in liver cirrhosis by modified Tuduzi Buqi Decoction combined with western medicine conventional therapy

A review and commentary on practice and progress of the liver fibrosis treatment with traditional Chinese medicine

Advances in the diagnosis and treatment of cirrhotic portal hypertension with integrated traditional Chinese and Western medicine

Practical application and development of activating blood and resolving stasis treatment method for liver cirrhosis

Related Author

No data

Related Institution

Institute of Liver Diseases， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Hepatology， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Infectious Disease （Hepatology）， The Affiliated Hospital of Hangzhou Normal University

Key Laboratory of Liver and Kidney Diseases， Ministry of Education

Shanghai Key Laboratory of Traditional Chinese Clinical Medicine

⁰